Trending...
- Black Women Living With, and Impacted by, HIV Express Gratitude, Grief, Joy, and Resilience
- Amaris Mint® Confirms UK Availability of Swedish-Made BioBoost Daily Nutrition Range
- MainConcept Easy Video API Extends Full Transcoding to Arm and NETINT VPUs
MADISON, Wis. ~ A new study published in Nature Communications has demonstrated how small molecule inhibitors can be used to improve the precision and efficiency of CRISPR-Cas9 gene editing. The research, led by scientists from AstraZeneca, was conducted with the help of Promega research scientists Marie Schwinn and Michael Slater.
CRISPR-Cas9 is a genome editing technique that has revolutionized biomedical research since it was first unveiled in 2012. It enables researchers to cut DNA at specific sites and insert or remove genetic material, allowing for a level of genetic manipulation that was previously impossible.
The authors analyzed a library of 20,548 small molecules to develop strategies for improving this gene editing technique. They identified two inhibitors targeting the proteins DNA-dependent Protein Kinase (DNA-PK) and DNA Polymerase Theta (PolΘ) and demonstrated that the combination of these two molecules dramatically increased the performance of "knock-in" gene editing. This strategy, dubbed 2iHDR, outperformed previously described strategies that aimed to increase knock-in efficiency with small molecule inhibitors.
More on Wisconsin Eagle
The paper also documents a new system based on next-generation sequencing (NGS) that can be used to characterize the effects of inhibitors on CRISPR-Cas9. This open-access tool, which the authors named KI-Seq, enables researchers to analyze the contributions of different DNA repair pathways following CRISPR-Cas9 treatment. Unlike comparable tools, KI-Seq can be used with any cell type, including non-dividing primary cells.
The findings from this study are key to advancing the use of CRISPR techniques in research and clinical applications using a wide range of cell lines. The paper titled "Simultaneous inhibition of DNA-PK and Polϴ improves integration efficiency and precision of genome editing" provides further information on this breakthrough discovery. Promega technologies that can be used with CRISPR-Cas9 are also available at www.promega.com/CRISPR for those interested in learning more about this technology.
CRISPR-Cas9 is a genome editing technique that has revolutionized biomedical research since it was first unveiled in 2012. It enables researchers to cut DNA at specific sites and insert or remove genetic material, allowing for a level of genetic manipulation that was previously impossible.
The authors analyzed a library of 20,548 small molecules to develop strategies for improving this gene editing technique. They identified two inhibitors targeting the proteins DNA-dependent Protein Kinase (DNA-PK) and DNA Polymerase Theta (PolΘ) and demonstrated that the combination of these two molecules dramatically increased the performance of "knock-in" gene editing. This strategy, dubbed 2iHDR, outperformed previously described strategies that aimed to increase knock-in efficiency with small molecule inhibitors.
More on Wisconsin Eagle
- Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
- Shelter Structures America makes European debut at TEMPOR EXPO 2026 in Fulda, Germany
- HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory
- Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
- OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
The paper also documents a new system based on next-generation sequencing (NGS) that can be used to characterize the effects of inhibitors on CRISPR-Cas9. This open-access tool, which the authors named KI-Seq, enables researchers to analyze the contributions of different DNA repair pathways following CRISPR-Cas9 treatment. Unlike comparable tools, KI-Seq can be used with any cell type, including non-dividing primary cells.
The findings from this study are key to advancing the use of CRISPR techniques in research and clinical applications using a wide range of cell lines. The paper titled "Simultaneous inhibition of DNA-PK and Polϴ improves integration efficiency and precision of genome editing" provides further information on this breakthrough discovery. Promega technologies that can be used with CRISPR-Cas9 are also available at www.promega.com/CRISPR for those interested in learning more about this technology.
0 Comments
Latest on Wisconsin Eagle
- STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
- Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
- Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
- Mandeville Pests May Pose Serious Health Risks for Your Family
- 32-inch Touchscreen Display ramps up game machine attraction
- Share your workplace safety solutions at 2027 Applied Ergonomics Conference
- Parents No Longer Have to Wait 3 Weeks for a Sleep Consultant: Nora Talks Tonight, Stays for 5 Days, Costs $89
- May The Worst Team Win! Loserball Kicks Off Another NFL Season of Hilarious Mayhem
- Black Women Living With, and Impacted by, HIV Express Gratitude, Grief, Joy, and Resilience
- MainConcept Easy Video API Extends Full Transcoding to Arm and NETINT VPUs
- Cruxy shortlisted for two Private Equity Wire® US Awards 2026: Advisory Firm of the Year (Overall) & Value Creation Consulting Firm of the Year
- Lake Norman Philharmonic - Free Community Concert
- Amaris Mint® Confirms UK Availability of Swedish-Made BioBoost Daily Nutrition Range
- Sea Tales Strengthens U.S. Leadership Team as Retail Expansion Accelerates
- Patented Foodservice Products Company with Strong Gross Margins and Substantial Two-Year Revenue Growth Hits Market for $1.6 Million
- Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A!
- Dividend Stacker Launches Free Calendar and Alerts for High-Yield ETF Payouts
- Paul Ohana - From Beverly Hills Salon Chair To Beauty Founder Celebrity Hair Expert
- ChargeOn Announces Conversational Payment Management Solution
- King Larry Steps Into His Moment With Music, Major Performances and a Story Built on Persistence